We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically hig... Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard. Show more
Ask ADVFN Intelligence (AI)
Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Virtual Summit PR Newswire NEW YORK, Oct. 9, 2024 NEW YORK, Oct. 9, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq:...
Lucid Diagnostics to Join Global Medtech Leaders at The MedTech Conference 2024 PR Newswire NEW YORK, Oct. 8, 2024 Company to showcase EsoGuard® and EsoCheck® at the conference's Innovation...
Lucid Diagnostics Holds Inaugural #CheckYourFoodTube Precancer Testing Event for Former NFL Players PR Newswire NEW YORK, Oct. 1, 2024 Initiative aims to increase awareness of the relationship...
American Foregut Society's 2024 Annual Meeting to Highlight Lucid Diagnostics' EsoGuard Esophageal Precancer Test PR Newswire NEW YORK, Sept. 24, 2024 Follows the Society's strong endorsement of...
PAVmed Announces Efforts to Regain Compliance with Nasdaq Listing Requirements PR Newswire NEW YORK, Sept. 16, 2024 Efforts include appointment of seasoned biotech investor Sundeep Agrawal, M.D...
Lucid Diagnostics to Host Symposium on Non-Endoscopic Esophageal Precancer Screening at the 20th International Society for Diseases of the Esophagus (ISDE) World Congress PR Newswire NEW YORK...
Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile Health PR Newswire NEW YORK, Sept. 3, 2024 Collaboration aims to enhance early detection of esophageal cancer in at-risk...
Lucid Diagnostics Announces Publication of Analytical Validation Study of EsoGuard® for Early Detection of Esophageal Precancer and Cancer PR Newswire NEW YORK, Aug. 20, 2024 Study demonstrates...
The American Foregut Society Formally Requests Medical Policy Coverage of EsoGuard® to Enhance Early Detection of Esophageal Cancer PR Newswire NEW YORK, Aug. 13, 2024 Request for insurance...
PAVmed Provides Business Update and Second Quarter 2024 Financial Results PR Newswire NEW YORK, Aug. 13, 2024 Lucid reports record quarterly EsoGuard® test volume and held productive meeting with...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.0473 | -5.67010309278 | 0.8342 | 0.85 | 0.7706 | 170151 | 0.80292278 | CS |
| 4 | -0.0571 | -6.7654028436 | 0.844 | 0.8739 | 0.73 | 190961 | 0.81678769 | CS |
| 12 | -0.0631 | -7.42352941176 | 0.85 | 0.9706 | 0.7201 | 180021 | 0.82287855 | CS |
| 26 | -0.1431 | -15.3870967742 | 0.93 | 1.11 | 0.6301 | 182924 | 0.83677698 | CS |
| 52 | -0.5631 | -41.7111111111 | 1.35 | 1.58 | 0.6301 | 137716 | 0.94501801 | CS |
| 156 | -11.9631 | -93.8282352941 | 12.75 | 13.5 | 0.6301 | 129506 | 3.03100747 | CS |
| 260 | -11.9631 | -93.8282352941 | 12.75 | 13.5 | 0.6301 | 129506 | 3.03100747 | CS |
Monksdream
7 months ago
Monksdream
1 year ago
ErnieBilco
2 years ago
makinezmoney
3 years ago
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
